All In Biotech

Drug Trial Radar · NCT07868835

Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants Without Type 2 Diabetes Mellitus Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 560 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

560

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jul 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Viking Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.

Conditions

  • Weight Loss

Interventions

  • VK2735Drug

    VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

  • Placebo comparatorDrug

    Placebo comparator administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in body weight for participants receiving VK2735 orally once dailyTime frame: 68 weeks

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Viking Clinical Site #1020

    Tucson, Arizona · Recruiting

  • Viking Clinical Site #1018

    Chula Vista, California · Recruiting

  • Viking Clinical Site #1015

    Lake Forest, California · Recruiting

  • Viking Clinical Site #1005

    Melbourne, Florida · Recruiting

  • Viking Clinical Site #1003

    The Villages, Florida · Recruiting

  • Viking Clinical Site #1013

    Atlanta, Georgia · Recruiting

  • Viking Clinical Site #1001

    Evansville, Indiana · Recruiting

  • Viking Clinical Site #1009

    Valparaiso, Indiana · Recruiting

  • Viking Clinical Site #1014

    Louisville, Kentucky · Recruiting

  • Viking Clinical Site #1004

    Richfield, Minnesota · Recruiting

  • Viking Clinical Site #1029

    Jackson, Mississippi · Recruiting

  • Viking Clinical Site #1028

    Springfield, Missouri · Recruiting

  • Viking Clinical Site #1006

    Rochester, New York · Recruiting

  • Viking Clinical Site #1035

    Morehead City, North Carolina · Recruiting

  • Viking Clinical Site #1023

    Medford, Oregon · Recruiting

  • Viking Clinical Site #1002

    East Greenwich, Rhode Island · Recruiting

  • Viking Clinical Site #1030

    Henderson, Tennessee · Recruiting

  • Viking Clinical Site #1031

    Abilene, Texas · Recruiting

  • Viking Clinical Site #1026

    Salt Lake City, Utah · Recruiting

  • Viking Clinical Site #1011

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.